Friday, February 3, 2023
HomeIndiaSerum Institute has applied for trials of Novavax vaccine, says Adar Poonawalla

Serum Institute has applied for trials of Novavax vaccine, says Adar Poonawalla

In a tweet, Serum Institute of India CEO Adar Poonawalla said, "Our partnership for a Covid-19 vaccine with Novavax has also published excellent efficacy results.”

Text Size:

Pune: Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said his company has applied to start the trials of another COVID-19 vaccine and that it hopes to launch it by June 2021.

The city-based firm has already produced Covishield vaccine, co-developed by the University of Oxford and British-Swedish company AstraZeneca. The Centre has purchased 11 million doses of Covishield vaccine for the ongoing inoculation drive.

In a tweet, Poonawalla said, “Our partnership for a COVID-19 vaccine with @Novavax has also published excellent efficacy results. We have also applied to start trials in India. Hope to launch #COVOVAX by June 2021!”

The country launched its COVID-19 vaccination drive from January 16 in what Prime Minister Narendra Modi has called the world’s largest inoculation programme with priority to be given to nearly three crore healthcare and frontline workers.


Subscribe to our channels on YouTube & Telegram

Support Our Journalism

India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that.

Sustaining this needs support from wonderful readers like you.

Whether you live in India or overseas, you can take a paid subscription by clicking here.

Support Our Journalism

Most Popular